Back to search

Article

A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF <sup>V600E</sup> colorectal tumors

2022-10-21

Abstract excerpt

<h4>ABSTRACT</h4> BRAF V600E mutation confers a poor prognosis in metastatic colorectal cancer (CRC) despite combinatorial targeted therapies based on the latest understanding of signaling circuitry. To identify parallel resistance mechanisms induced by BRAF/MEK/EGFR co-targeting, we used a high throughput kinase activity mapping platform. We found that SRC kinases are systematically activated in BRAF V600E CRC...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c175cefc-7cf2-554c-a820-e2d8d5962c2d
DOI
10.1101/2022.10.20.512885
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF <sup>V600E</sup> colorectal tumorsDOI 10.1101/2022.10.20.512885
An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapySemantic proximity
Acquired resistance to BRAF inhibitory treatments requires tumor tissue remodeling and reveals targetable vulnerabilities in colorectal cancerSemantic proximity
A system-wide approach to monitor responses to synergistic BRAF and EGFR inhibition in colorectal cancer cellsSemantic proximity
Targeting the ERK/MAPK Pathway in Cancer: Oncogenic Mechanisms, Therapeutic Resistance, and Emerging Gene-Based StrategiesSemantic proximity
Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF InhibitorsSemantic proximity
A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells.Semantic proximity
The AhR-SRC axis as a therapeutic vulnerability in BRAFi-resistant melanoma.Semantic proximity
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.Semantic proximity
Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistanceSemantic proximity
Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary ConvergenceSemantic proximity
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.Semantic proximity
Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant CancersSemantic proximity
Select a neighboring publication to make it the new centre.